Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics filed a Form S-3 shelf registration to offer up to $300,000,000 of securities, including a separate sale-agreement prospectus to sell up to $50,000,000 of common stock under an at-the-market agreement with Jefferies LLC. The prospectus states the company is a clinical-stage developer of off-the-shelf viral immunotherapies. The lead adenovirus candidate, CAN-2409, recently completed a successful Phase 3 trial in localized prostate cancer and produced positive Phase 2a results in non-small cell lung cancer and borderline resectable pancreatic ductal adenocarcinoma. The HSV-based candidate CAN-3110 is in an ongoing investigator-sponsored Phase 1b trial for recurrent high-grade glioma.
The document discloses Nasdaq listing (ticker CADL) with a closing price of $6.35 on August 12, 2025, 54,895,099 shares outstanding as of August 1, 2025, and outstanding Series B warrants (3,672,484 unconditional and up to 3,672,484 conditional). Use of proceeds is described as working capital, R&D, manufacturing, clinical trials and potential acquisitions. The company identifies itself as an emerging growth company and a smaller reporting company and includes corporate governance provisions such as a classified board and broad preferred-stock authorization.
Candel Therapeutics, Inc. (CADL) reported interim results showing material clinical progress and a strengthened balance sheet as of June 30, 2025. Cash and cash equivalents totaled $100.7 million and total assets were $105.97 million. For the six months ended June 30, 2025 the company reported net income of $2.6 million, driven largely by a $20.6 million favorable change in the fair value of a warrant liability, compared with a net loss of $30.5 million in the prior-year period. The company recorded operating expenses of $19.3 million for the six months.
On the clinical front, CAN-2409 achieved a positive phase 3 result in intermediate-to-high-risk localized prostate cancer under an FDA SPA (p=0.0155; HR 0.70), with median DFS not reached vs. 86.1 months for placebo. Management expects to submit a biologics license application in Q4 2026. Additional positive clinical data were reported for CAN-2409 in NSCLC and pancreatic cancer and ongoing CAN-3110 data support repeat-dosing exploration. The filing also discloses an accumulated deficit of $189.6 million, a current term loan balance and the company’s statement that additional financing will be required to fund operations beyond the next 12 months if circumstances change.
Candel Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025. The company reported these quarterly results through a press release dated August 14, 2025, which is attached as Exhibit 99.1 to this Form 8-K.
The information about these results, including the press release, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Candel Therapeutics by President and Chief Executive Officer Paul Peter Tak, M.D., Ph.D., FMedSci.
Candel Therapeutics (CADL) reported a significant insider purchase by CEO and Director Paul Peter Tak on June 25, 2025. The transaction involved the acquisition of 42,826 shares at $4.67 per share through a registered direct offering, representing a total investment of approximately $200,000.
Following this transaction, Tak's direct beneficial ownership increased to 268,566 shares. The purchase was executed pursuant to a Securities Purchase Agreement dated June 23, 2025, demonstrating insider confidence in the company's prospects.
Key Transaction Details:
- Transaction Type: Direct Purchase (registered offering)
- Share Price: $4.67
- Total Shares Post-Transaction: 268,566
- Filing Date: June 28, 2025
- Transaction Form: Form 4 (Statement of Changes in Beneficial Ownership)
Paul B. Manning, Director of Candel Therapeutics (CADL), reported significant insider transactions on June 25, 2025. Manning acquired 1,070,663 shares at $4.67 per share through a registered direct offering, demonstrating substantial insider investment totaling approximately $5 million.
Following the transaction, Manning's beneficial ownership includes:
- 2,213,069 shares held indirectly through the Paul B. Manning Revocable Trust
- 1,303,752 shares held indirectly through BKB Growth Investments, LLC
- 1,681,000 shares held directly (jointly with spouse)
The total beneficial ownership amounts to 5,197,821 shares, indicating significant insider confidence in the company. The purchase was made pursuant to a Securities Purchase Agreement dated June 23, 2025, suggesting a planned strategic investment in the company's future.
Christopher Martell, Director of Candel Therapeutics (CADL), reported significant insider transactions and holdings on June 28, 2025:
Key Transaction: Acquired 111,349 shares of Common Stock at $4.67 per share on June 25, 2025, through a registered direct offering. These shares are held indirectly through his spouse.
Additional Indirect Holdings:
- 152,000 shares held through GTAM1 2012 LLC (trust where Martell serves as trustee)
- 283,514 shares held through GTAM1 2012 ADV LLC (where Martell serves as manager)
Total beneficial ownership across all indirect holdings amounts to 546,863 shares. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Martell disclaims beneficial ownership of trust-held shares except for his pecuniary interest.